These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 15111846)

  • 21. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.
    Sever PS; Chang CL; Gupta AK; Whitehouse A; Poulter NR;
    Eur Heart J; 2011 Oct; 32(20):2525-32. PubMed ID: 21873710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
    Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
    Gresser U; Gathof BS
    Eur J Med Res; 2004 Jan; 9(1):1-17. PubMed ID: 14766335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
    Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
    J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery.
    Chello M; Patti G; Candura D; Mastrobuoni S; Di Sciascio G; Agrò F; Carassiti M; Covino E
    Crit Care Med; 2006 Mar; 34(3):660-7. PubMed ID: 16505650
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
    Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The collaborative atorvastatin diabetes study: preliminary results.
    Owen OG
    Int J Clin Pract; 2005 Jan; 59(1):121-3. PubMed ID: 15707477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
    Swindle JP; Potash J; Kulakodlu M; Kuznik A; Buikema A
    Am J Geriatr Pharmacother; 2011 Dec; 9(6):471-82. PubMed ID: 22019005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study.
    Wenger NK; Lewis SJ; Welty FK; Herrington DM; Bittner V;
    Heart; 2008 Apr; 94(4):434-9. PubMed ID: 18070940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
    Rouleau J
    Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
    Cannon CP; Braunwald E; McCabe CH; Rader DJ; Rouleau JL; Belder R; Joyal SV; Hill KA; Pfeffer MA; Skene AM;
    N Engl J Med; 2004 Apr; 350(15):1495-504. PubMed ID: 15007110
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of perioperative beta-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial.
    Yang H; Raymer K; Butler R; Parlow J; Roberts R
    Am Heart J; 2006 Nov; 152(5):983-90. PubMed ID: 17070177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
    Koren MJ; Hunninghake DB;
    J Am Coll Cardiol; 2004 Nov; 44(9):1772-9. PubMed ID: 15519006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
    Schwartz GG; Olsson AG; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A; Chaitman BR; Leslie S; Stern T;
    JAMA; 2001 Apr; 285(13):1711-8. PubMed ID: 11277825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
    Jukema JW; Liem AH; Dunselman PH; van der Sloot JA; Lok DJ; Zwinderman AH
    Curr Med Res Opin; 2005 Nov; 21(11):1865-74. PubMed ID: 16307708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are early clinical effects of cholesterol lowering mediated through effects on inflammation?
    Olsson AG; Schwartz GG; Jonasson L; Linderfalk C
    Acta Physiol Scand; 2002 Oct; 176(2):147-50. PubMed ID: 12354174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pilot double-blind, randomized controlled trial of short-term atorvastatin for prevention of acute kidney injury after cardiac surgery.
    Prowle JR; Calzavacca P; Licari E; Ligabo EV; Echeverri JE; Haase M; Haase-Fielitz A; Bagshaw SM; Devarajan P; Bellomo R
    Nephrology (Carlton); 2012 Mar; 17(3):215-24. PubMed ID: 22117606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.